Physiopathology of pain in rheumatology

Reumatismo

Volumn 66, Issue 1, 2014, Pages 4-13

  Cazzola, Marco ^a   Atzeni, F ^b   Boccassini, L ^b   Cassisi, G ^c   Sarzi Puttini, P ^b  

^a Unit of Rehabilitation Medicine   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Rheumatology Branch   (Italy)

Author keywords

Allodynia; Chronic rheumatic diseases; Hyperalgesia; Peripheral mechanisms

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITONIN GENE RELATED PEPTIDE; INTERLEUKIN 1; INTERLEUKIN 6; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AUTONOMIC NERVOUS SYSTEM; BRAIN FUNCTION; CENTRAL SENSITISATION; DISEASE ASSOCIATION; EMOTION; EXECUTIVE FUNCTION; GENE MUTATION; HUMAN; IMMUNE SYSTEM; MUSCULOSKELETAL PAIN; NEUROMODULATION; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PERIPHERAL SENSITISATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SENSITIZATION; STRESS; STRESS REACTION SYSTEM; ADAPTIVE BEHAVIOR; ANALGESIA; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHRONIC PAIN; COMPLICATION; DEPRESSION; HYPERALGESIA; IMMUNOLOGY; IMMUNOMODULATION; PAIN RECEPTOR; PERIPHERAL NERVOUS SYSTEM; PHYSIOLOGY; POSTERIOR HORN CELL; PSYCHOLOGY; RHEUMATIC DISEASE;

ADAPTATION, PSYCHOLOGICAL; AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHRONIC PAIN; DEPRESSION; HUMANS; HYPERALGESIA; MUSCULOSKELETAL PAIN; NERVE GROWTH FACTORS; NEUROIMMUNOMODULATION; NEUROTRANSMITTER AGENTS; NOCICEPTORS; PAIN MANAGEMENT; PAIN PERCEPTION; PERIPHERAL NERVOUS SYSTEM; POSTERIOR HORN CELLS; RHEUMATIC DISEASES;

EID: 84902203031     PISSN: 00487449     EISSN: 22402683     Source Type: Journal    
DOI: 10.4081/reumatismo.2014.758     Document Type: Review

References (90)

1. Merskey H, Bogduk N. Classification of chronic pain. 2nd ed. Seattle: IASP Press; 1994.
2. Kidd BL, Morris VA, Urban L. Pathophysiology of joint pain. Ann Rhem Dis. 1996; 55: 276-83.
3. Jones AKP, Derbyshire SWG. Cerebral mechanism operating in the presence and absence of inflammatory pain. Ann Rheum Dis. 1996; 55: 411-20.
4. Gerwin RD. Neurobiology of the myofascial trigger point. Bailliere's Clin Rheumatol. 1994; 8: 747-62.
5. Rang HP, Bevan S, Dray A. Nociceptive peripheral neurones: cellular properties. In: Wall PD, Melzack M, eds. Textbook of pain, 3rd ed. Edinburgh: Churcill Livingstone; 1994; 57-8.
6. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008; 9: 116.
7. Yunus MB. Dysfunctional spectrum syndrome: a unified concept for many common maladies. Fibromyalgia Frontiers. 1996; 4: 3.
8. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. 2007; 36: 339-56.
9. Winfield JB. Fibromyalgia and related central sensitivity syndromes: twenty-five years of progress. Semin Arthritis Rheum. 2007; 36: 335-8.
10. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum. 2008; 37: 339-52.
11. Cazzola M, Sarzi Puttini PC, Stisi S, Di Franco M, Bazzichi L, Carignola R, et al. (Italian Fibromyalgia Network). Fibromyalgia syndrome: definition and diagnostic aspects. Reumatismo. 2008; 60 (Suppl. 1): 3-14.
12. Stisi S, Cazzola M, Buskila D, Spath M, Giamberardino MA, Sarzi Puttini PC, et al. (Italian Fibromyalgia Network). Etiopathogenetic mechanism of fibromyalgia syndrome. Reumatismo 2008; 60 (1 suppl): 25-35.
13. Phillips K, Clauw DJ. Central pain mechanism in chronic pain states-Maybe it is all in their head. Best Pract Res Clin Rheumatol. 2011; 25: 141-54.
14. Jensen KB, Kosek E, Petzke F, Carville S, Fransson P, Marcus H, et al. Evidence of dysfunctional pain inhibition in fibromyalgia reflected in rACC during provoked pain. Pain. 2009; 145: 95-100.
15. Goffaux P, Barcellos de Souza J, Potvin S, Marchand S. Pain relief through expectation supersedes descending inhibitory deficits in fibromyalgia patients. Pain. 2009; 145: 18-23.
16. Lutz J, Jager L, de Quervain D, Krauseneck T, Padberg F, Wichnalek M, et al. White and gray matter abnormalities in the brain of patients with fibromyalgia. Arthritis Rheum. 2008; 58: 3960-69.
17. Kwiatek R, Barnden L, Tedman R, Jarrett R, Chew J, Rowe C, et al. Regional blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum. 2000; 43: 2823-33.
18. Gracely RH, Petke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002; 46: 1333-43.
19. Pujol J, Lopez-Sola M, Ortiz H, Vilanova JC, Harrison BJ, Yucel M, et al. Mapping brain response to pain in fibromyalgia patients using temporal analysis of fMRI. PLoS ONE. 2009; 4: e5224.
20. Emand Y, Ragab Y, Zeinhom F, El-Khouly G, Abou-Zeid A, Rasker JJ. Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheumatol. 2008; 35:1371-7.
21. Petrou M, Harris RE, Foerster BR, Mclean SA, Sen A, Clauw DJ, et al. Proton MR spectroscopy in the evaluation of cerebral metabolism in patients with fibromyalgia: comparison with healthy controls and correlation with symptom severity. Am J Neuroradiol. 2008; 29: 913-8.
22. Meus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007; 26: 465-73.
23. Yunus MB. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract Res Clin Rheumatol. 2007; 21: 481-97.
24. Kindler LL, Bennett RM, Jones KD. Central sensitivity syndromes: mounting pathophysiologic evidence to link fibromyalgia with other chronic pain disorders. Pain Manag Nurs. 2011; 12: 15-24.
25. Kosek E, Ordeberg G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur J Pain. 2000; 4: 229-38.
26. Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthrit Res Ther. 2011; 13: 211.
27. Bhave G, Gereau IV RV. Posttranslational mechanism of peripheral sensitization. J Neurobiol. 2004; 61: 88-106.
28. Clifford JW, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A. 1999; 96: 7723-30.
29. Miura M, Sasaki M, Mizukoshi K, Shibasaki M, Izumi Y, Shimosato G, et al. Peripheral sensitization caused by insulin-like growth factor 1 contributes to pain hypersensitivity after tissue injury. Pain. 2011; 152: 888-95.
30. Kim SH, Jang TJ, Moon IS. Increased expression of N-methyl-D-aspartate receptor subunit 2D in the skin of patients with fibromyalgia. J Rheumatol. 2006; 33: 785-8.
31. Selemi S, Rethage J, Wollina U, Michel BA, Gay RE, Gay S, et al. Detection of interleukin 1 beta (IL-1 beta), IL-6 and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol. 2003; 30: 146-50.
32. Blanco I, Beritze N, Arguelles M, Carcaba V, Fernandez F, Janciauskiene S, et al. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol. 2010; 29: 1403-12.
33. Gerdle B, Soderberg K, Salvador Puigvert L, Rosendal L, Larsson B. Increased interstizial concentrations of pyruvate and lactate in the trapezius muscle of patients with fibromyalgia: a microdialysis study. J Rehabil Med. 2010; 42: 679-87.
34. Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol. 2005; 99: 1977-84.
35. Abe Y, Akeda K, An HS, Aoki Y, Pichika R, Muehleman C, et al. Proinflammatory cytokines stimulate the expression of nerve growth factor by human intervertebral disc cells. Spine. 2007; 32: 635-42.
36. Thomas Cheng H. Spinal cord mechanism of chronic pain and clinical implications. Curr Pain Headache Rep. 2010; 14: 213-20.
37. Cheng JK, Ru-Rong JI. Intracellular signalling in primary sensory neurons and persistent pain. Neurochem Res. 2008; 33: 1970-8.
38. Russel IJ. Substance P and fibromyalgia. J Musculoskel Pain. 1998; 6: 29-35.
39. Welin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in metenkephalin-arg-phe levels in CSF from fibromyalgia patients. J Musculoskel Pain. 1995; 3: 4.
40. Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate and the link between migraine and fibromyalgia. Curr Pain Headache Rep. 2007; 11: 343-51.
41. Giovengo SL, Russel IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999; 26: 1564-9.
42. Sarchielli P, Alberti A, Candeliere A, Floridi A, Capocchi G, Calabresi P. Glial cell linederived neurotrophic factor and somatostatin levels in cerebrospinal fluid of patients affected by chronic migraine and fibromyalgia. Cephalalgia. 2005; 26: 409-15.
43. Ren K. Descending control mechanism. In: Basbaum A, Bushnell M, eds. Science of pain. San Diego, CA: Elsevier. 2009; 723-63.
44. Gwilym SE, Keltner JR, Warnaby CE, Carr AJ, Chizh B, Chessel I, et al. Psychophysical and functional imaging supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum. 2009; 61: 1226-34.
45. Arendt-Nielsen L, Nie H, Laursen MB, Laursen BS, Madeleine P, Simonsen OH, et al. Sensitization in patients with painful knee osteoarthritis. Pain. 2010; 149: 573-81.
46. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nature Med. 2010; 16: 1267-76.
47. Devor M. Nerve pathophysiology and mechanism of pain in causalgia. J Auton Nerv Syst. 1983; 7: 371-84.
48. Stanton-Hicks M, Janing W, Hassen-Buck S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995; 63: 127-33.
49. Cheng HT, Dauch JR, Hayes JM, Hong Y, Feldman EL. Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes. J Neuropathol Exp Neurol 2009; 68: 1229-43.
50. Pappagallo M, Shaiova L, Perlov E, Knotkova H. Difficult pain syndromes: bone pain, visceral pain, neuropathic pain. In: Berger AM, Shuster JL, Von Roenn JH, eds. Principles and practice of palliative pain and supportive oncology. Philadelphia: Lippincott Williams & Wilkins; 2006.
51. Eibl JK, Chapelsky SA, Ross GM. Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor. J Pharmacol Exp Ther. 2010; 332: 446-54.
52. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005; 115: 128-41.
53. Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 2005; 65: 9426-35.
54. Staud R. Is it all central sensitization? Role of peripheral tissue nociception in chronic musculoskeletal pain. Curr Rheumatol Rep. 2010; 12: 448-54.
55. Staud R, Nagel S, Robinson ME, Price DD. Enhanced central pain processing is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain 2009; 145: 96-104.
56. Chrousos G, Gold P. The concept of stress and stress system disorders. JAMA. 1992; 267: 1244-52.
57. Chrousos G. The hypothalamic-pituitary-adrenal axis and the immune-mediated inflammation. N Engl J Med. 1995; 332: 1351-62.
58. Plotsky PM. Stress system plasticity: neural adaptations to neonatal pain and stress. J Musculoskel Pain. 1998; 3: 57-60.
59. Chrousos GP. Neuroendocrine alterations associated with altered sleep, mood and pain perception. J Musculoskel Pain. 1998; 6: 51-5.
60. Neeck G, Riedel W. Neuromediator and hormonal perturbations in fibromyalgia syndrome: results of chronic stress? Bailliere's Clin Rheumatol. 1994; 8: 763-75.
61. Dailey PA, Bishop GD, Russel IJ, Fletcher EM. Psychological stress and the fibrositis/fibromyalgia syndrome. J Rheumatol. 1990; 15: 541-58.
62. Uveges JM, Parker JC, Smarr KL, McGowan JF, Lyon MG, Irvin WS, et al. Psychological symptoms in primary fibromyalgia syndrome: relationship to pain, life stress and sleep disturbance. Arthritis Rheum. 1990; 33: 1279-83.
63. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994; 37: 1583-92.
64. Griep EN, Boersma JW, Lentjes EEF, Prins AP, van der Korst JK, de Kloet ER. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol. 1998; 25: 145-8.
65. Chen X, Green PG, Levine DJ. Stress enhances muscle nociceptor activity in the rat. Neuroscience. 2011; 185: 166-73.
66. Vossen H, Kenis G, Rutten B, van OS J, Hermens H, Lousberg R. The genetic influence on the cortical processing of experimental pain and the moderating effect of pain status. PLoS ONE. 2010; 5: e13641.
67. Williams FMK, Scollen S, Cao D, Memari Y, Hyde CL, Zhang B, et al. Genes contributing to pain sensitivity in the normal population: an exome sequencing study. PLoS Genet. 2012; 8: e1003095.
68. Hocking LJ. Heritability of chronic pain in 2195 extended families. Eur J Pain. 2012; 16: 1053-63.
69. Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The NAV 1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013; 14: 49-62.
70. Cregg R, Laguda B, Werdehausen R, Cox JJ, Linley JE, Ramirez JD, et al. Novel mutations mapping to the fourth sodium channel domain of NAV 1.7 result in variable clinical manifestations of primary erythromelalgia. Neuromolecular Med. 2013; 15: 265-78.
71. Mert T, Gunes Y. Antinociceptive activities of lidocaine and the NAV 1.8 blocker a803464 in diabetic rats. J Am Assoc Lab Anim Sci. 2012; 51: 579-85.
72. Buskila D, Sarzi Puttini P. Genetic aspects of fibromyalgia syndrome. Arthrit Res Ther. 2006; 8: 218.
73. Van Meurs JBJ, Uitterlinden AG, Stolk L, Kerkhof HJM, Hofman A, Pols H, et al. A functional polymorphism in the catecol-Omethyltransferase gene is associated with osteoarthritis-related pain. Arthritis Rheum. 2009; 60: 321-4.
74. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995; 38: 19-28.
75. Epstein SA, Clauw D, Klein D, Heaton R, Klein D, Krupp L, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics. 1999; 40: 57-63.
76. Hazlett DJ, Haines SN. Fibromyalgia: a time series analysis of the stressor-physical symptom association. J Behav Med. 1992; 15: 541-8.
77. White KP, Harth M, Speechley M, Ostbye T. A general population study of fibromyalgia tender points in nonistituzionalized adults with chronic widespread pain. J Rheumatol. 2001; 27: 2677-82.
78. Torta R. La depressione come malattia sistemica e lo spettro d'azione della terapia antidepressiva. Roma: Critical Medicine Publ.; 2008.
79. Vichers MC, Maes M. The role of indolamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci. 2004; 29: 11-7.
80. Keefe FJ, Lefebvre JC: Pain behaviour concepts: controversies, current status, and future directions. In Gebhart GF, Hammond DL, Jensen TS, editors. Proceedings of the Seventh World Congress on Pain. Seattle, IASP Press, 1994:127.
81. Flor H, Birmbauer N: Basic issues in the psychobiology of pain. In Gebhart GF, Hammond DL, Jensen TS, editors: Proceedings of the Seventh World Congress on Pain. Seattle, IASP Press, 1994:113.
82. Hassett AL, Cone JD, Patella SJ, Sigal LH. The role of catastrophizing in the pain and depression of women with the fibromyalgia syndrome. Arthritis Rheum. 2000; 43: 2493-500.
83. Pilowsky I. Abnormal illness behaviour. Br J Med Psychol. 1969; 42: 347-51.
84. Ercolani M, Trombini G, Chattat R, Cervini C, Piergiacomi G, Salaffi F, et al. Fibromialgic syndrome: depression and abnormal illness behaviour. Multicentre investigation. Psychother Psychosom. 1994; 61: 178-86.
85. Bennett RM. Fibromyalgia and the disability dilemma. Arthritis Rheum. 1996; 10: 1627-34.
86. Winfield JB. Pain in fibromyalgia. Rheum Dis Clin North Am. 1999; 25: 55-79.
87. Lethem J, Slade PA, Troup JDG, Bentley G. Outline of a fear-avoidance model of exaggerated pain perceptions. Behav Res Ther. 1983; 21: 401-8.
88. Vlaeyen JVS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain. 2000; 85: 317-32.
89. Edwards CL, Fillingim RB, Keefe F. Race, ethnicity and pain. Pain. 2001; 94: 133-7.
90. Sheffield D, Biles PL, Orom H, Maixner W, Sheps DS. Race and sex differences in cutaneous pain perception. Psychosom Med. 2000; 62: 517-23.